- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01834677
Translational Research Evaluating Neurocognitive Memory Processes (TREC-MP)
The purpose of this study is to evaluate the psychometric properties and utility of new, computerized, neurocognitive measures in humans with depression, and humans with depression undergoing electroconvulsive therapy (ECT). The benefits of the study outweigh the risk as there is the possibility of developing better computerized neurocognitive measures, and the risks are limited to no more than minimal test related fatigue and psychological stress.
Depressed humans, depressed human participants undergoing ECT, and humans diagnosed with Parkinson's disease (age 18-85) will be invited to participate in this study. After providing informed consent participants will undergo a clinical psychiatric evaluation to confirm the inclusion/exclusion criteria. After the clinical psychiatric evaluation, participants will complete common and new neurocognitive measures. There will be a total of two testing visits (baseline, 1-month follow-up). The anticipated duration of the participant's involvement is no more than 2 study visits that can take place over a 4-day period (i.e., the clinical evaluation can occur on day 1 and the neuropsychological measures can be administered on day 2 of each study visit) equating to approximately 6-hours (3-hours each day) per study visit.
Studienübersicht
Status
Bedingungen
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
North Carolina
-
Durham, North Carolina, Vereinigte Staaten, 27710
- Duke Universtiy Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:Depressed Individuals
- Male and female subjects, age 18-85
- DSM-IV-TR diagnosis of major depressive episode, unipolar, confirmed by the MINI-PLUS [221]
- HRSD24 total score > 10
- MMSE total score > 26
- Graduated from high school
- Competent to provide informed consent
Inclusion Criteria:Depressed Individuals Receiving ECT
- Same as for Depressed Cohort Inclusion Criteria (see above)
- Referred for ECT
- Subject competent to provide informed consent
Inclusion Criteria:Individuals Diagnosed with PD
- Male and female subjects, age 18-85
- Diagnosed with PD
- MMSE total score > 20
- Graduate high school
- Subject competent to provide informed consent
Exclusion Criteria:Depressed Individuals/Depressed Individuals Receiving ECT
- Lifetime history of bipolar disorder, schizophrenia, schizoaffective disorder, or mental retardation
- Current neurostimulation treatment (e.g., ECT, MST, rTMS, vagus nerve stimulation, deep brain stimulation)
- Current alcohol abuse or dependence within past 12 months
- Current substance abuse or dependence within past 12 months
- Lifetime mental retardation
- History of central nervous system (CNS) disease
- Current diagnosis of dementia or delirium
- Current visual, auditory, or motor impairment that compromises ability to take tests
- Unable to read or comprehend English
Exclusion Criteria:Individuals Diagnosed with PD
- Lifetime history of bipolar disorder, schizophrenia, schizoaffective disorder, or mental retardation
- Current neurostimulation treatment (e.g., ECT, MST, rTMS, vagus nerve stimulation, deep brain stimulation)
- Current alcohol abuse or dependence within past 12 months
- Current substance abuse or dependence within past 12 months
- Lifetime mental retardation
- History of central nervous system (CNS) disease other than Parkinson's Disease
- Current diagnosis of dementia or delirium
- Current visual, auditory, or motor impairment that compromises ability to take tests
- Unable to read or comprehend English
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
Healthy Human
|
|
Depressed Human
|
|
Depressed Human, Undergoing Electroconvulsive Therapy
Electroconvulsive Therapy is being received as standard of care, not as a study intervention.
|
|
Human Diagnosed with Parkinson's Disease
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
California Verbal Learning Test-II
Zeitfenster: Baseline
|
The California Verbal Learning Test-II (CVLT-II) is a standard neuropsychological instrument that assesses verbal learning and memory.
|
Baseline
|
|
California Verbal Learning Test-II
Zeitfenster: 1-Month Follow-up
|
The California Verbal Learning Test-II (CVLT-II) is a standard neuropsychological instrument that assesses verbal learning and memory.
|
1-Month Follow-up
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Shawn McClintock, PhD, Duke University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- Pro00039288
- 5K23MH087739-03 (US NIH Stipendium/Vertrag)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .